Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab pharmacokinetics and safety in children with uncontrolled chronic spontaneous urticaria
jRCT2031220733Completed
- Sponsor
- Sanofi
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of dupilumab in chronic idiopathic urticaria (CIU), sponsored by Sanofi. Primary endpoint: Concentration of dupilumab in serum over time including trough concentration at Week 12 and Week 24. Started May 2023; status: completed.
02
Drugs
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2031220733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220733.